Slower 3Q growth at Novo Nordisk as Victoza comes under pressure
This article was originally published in Scrip
Executive Summary
Novo Nordisk reported slower-than-expected growth of its blockbuster Victoza in the third quarter, contributing to the world's biggest insulin maker missing analysts' estimates for third quarter income. The company also noted in its 3Q announcement that from 31 October 2013, it is making all its trial data public.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.